Bristol Myers Squibb (CELG-RI) Inventory (2009 - 2026)

Bristol Myers Squibb has disclosed Inventory across 18 years of filings, most recently posting $2.8 billion for Q1 2026.

• In Q1 2026, Inventory rose 3.38% year-over-year to $2.8 billion; the TTM figure through Mar 2026 stood at $2.8 billion (up 3.38% YoY), while the FY2025 annual figure was $2.7 billion, up 5.2% from the prior year.
• Inventory climbed to $2.8 billion in Q1 2026, from $2.7 billion in the prior quarter.
• Over the last five years, Inventory for CELG-RI reached as high as $3.3 billion in Q3 2024 and fell as low as $2.1 billion in Q3 2022.
• The 5-year median for Inventory is $2.7 billion (2023), against an average of $2.6 billion.
• Annual changes were most pronounced in 2024 — Inventory soared 36.78% — and 2025, when it dropped 17.23%.
• A 5-year view of Inventory shows it stood at $2.3 billion in 2022, then rose by 13.81% to $2.7 billion in 2023, then decreased by 3.94% to $2.6 billion in 2024, then increased by 5.2% to $2.7 billion in 2025, then gained by 2.45% to $2.8 billion in 2026.
• According to Business Quant data, Inventory over the past three periods registered $2.8 billion, $2.7 billion, and $2.8 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.